EP Patent

EP4023644A1 — Process for the preparation of a pharmaceutical agent

Assigned to Zaklady Farmaceutyczne Polpharma SA · Expires 2022-07-06 · 4y expired

What this patent protects

This invention relates to a process for the preparation of empagliflozin comprising lithiation of (3S)-3-[4-(5-bromo-2-chlorobenzyl)phenoxy]tetrahydrofuran using lithium reagent, coupling the lithiated anion species with (3R,4S,5R,6R)-3,4,5-tris[(trimethylsilyl)oxy]-6-{[(trimethy…

USPTO Abstract

This invention relates to a process for the preparation of empagliflozin comprising lithiation of (3S)-3-[4-(5-bromo-2-chlorobenzyl)phenoxy]tetrahydrofuran using lithium reagent, coupling the lithiated anion species with (3R,4S,5R,6R)-3,4,5-tris[(trimethylsilyl)oxy]-6-{[(trimethylsilyl)oxy]methyl}tetrahydro-2H-pyran-2-one and reducing the product methyl 1-C-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-α-D-glucopyranoside] using triethylsilane and boron trifluoride diethyl etherate and optionally purifying the crude product, wherein the reduction is conducted in the presence of molecular sieves.

Drugs covered by this patent

Patent Metadata

Patent number
EP4023644A1
Jurisdiction
EP
Classification
—
Expires
2022-07-06
Drug substance claim
No
Drug product claim
No
Assignee
Zaklady Farmaceutyczne Polpharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.